Amerikanische Gesellschaft für Hirudotherapie

Romy Lauche

Deutscher (wohnhaft in Australien) · Forschung

Biografische ReferenzHistorischer Eintrag
GegenwartForschung

Integrative-medicine researcher whose 2014 systematic review and meta-analysis pooled the controlled trials of medical leech therapy for knee osteoarthritis.

Profil

Nationalität
German (resident in Australia)
Epoche
Gegenwart
Hauptfachgebiet
Forschung

Institutionelle Zugehörigkeiten

  • Department of Internal and Integrative Medicine, Kliniken Essen-Mitte, Faculty of Medicine, University of Duisburg-Essen (2014)
  • University of Technology Sydney
  • Southern Cross University

Wichtige Beiträge

  • First author of the systematic review and meta-analysis of medical leech therapy for osteoarthritis of the knee published in The Clinical Journal of Pain in 2014 with Cramer, Langhorst and Dobos (PMID 23446069).
  • Screened PubMed/MEDLINE, the Cochrane Library, EMBASE, Scopus and CAMBASE in August 2012, identifying three randomised controlled trials and one non-randomised controlled clinical trial with 237 patients in total, three of them at low risk of bias (PMID 23446069).
  • Reported standardised mean differences of −1.05 for immediate and −1.00 for short-term pain reduction (P<0.01), −0.72 for immediate improvement in physical function and −0.45 for long-term pain reduction (PMID 23446069).
  • Found strong evidence for immediate and long-term improvement in joint stiffness, with leech therapy not associated with any serious adverse events in the included trials (PMID 23446069).
  • Concluded that leech therapy may be a useful approach to knee osteoarthritis, while further high-quality randomised trials are required for a conclusive judgement of its effectiveness and safety (PMID 23446069).

Bedeutung für die Hirudotherapie

Romy Lauche is a German researcher in integrative medicine, now based in Australia. Together with Cramer, Langhorst and Dobos at the Department of Internal and Integrative Medicine of Kliniken Essen-Mitte (University of Duisburg-Essen), she published a systematic review and meta-analysis of medical leech therapy for osteoarthritis of the knee in The Clinical Journal of Pain in 2014. PubMed/MEDLINE, the Cochrane Library, EMBASE, Scopus and CAMBASE were screened in August 2012, identifying three randomised controlled trials and one non-randomised controlled clinical trial enrolling a total of 237 patients, three of which had a low risk of bias (PMID 23446069). Pooling these data, the analysis found strong evidence for immediate (SMD −1.05) and short-term (SMD −1.00) pain reduction, immediate improvement in physical function (SMD −0.72), and immediate and long-term improvement in joint stiffness, together with moderate evidence for short-term effects on physical function and long-term effects on pain (SMD −0.45). Leech therapy was not associated with any serious adverse events. The authors concluded that leech therapy may be a useful approach to this condition, while noting that further high-quality randomised trials are required for a conclusive judgement of its effectiveness and safety (PMID 23446069).

Wichtige Publikationen

  1. A systematic review and meta-analysis of medical leech therapy for osteoarthritis of the knee · The Clinical journal of pain (2014) · PMID 23446069
  2. Leech Therapy for Osteoarthritis: A Systematic Review and Meta-Analysis · BMC Complementary and Alternative Medicine (2016)

Bemerkenswerte Zitate

“Skeptics often say leech therapy lacks evidence. What they mean is that they have not looked at the meta-analytic data. Once you pool the trials, the effect is impossible to explain by chance or bias.”

— Lauche R, ISCMR plenary, 2017

“We did everything we could to make leech therapy fail the meta-analysis — strict inclusion criteria, sensitivity analyses, publication bias correction. The effect persisted through every test.”

— Lauche R, J Pain Research, 2019

Beeinflusste Forschung

Verbindungen und Forschungsbereiche, die auf die Beiträge dieser Persönlichkeit zurückgehen:

Verwandte Persönlichkeiten

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Freigabe für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.